Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan

BACKGROUND: Breast-cancer incidence and mortality have been increasing in Japan. Japanese-specific clinical validity and utility data for the 21-gene assay (Oncotype DX® Breast Cancer Assay; Genomic Health, Inc., Redwood City, USA) are now available. The objective of this study was to evaluate the c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yamauchi, Hideko, Nakagawa, Chizuko, Yamashige, Shinji, Takei, Hiroyuki, Yagata, Hiroshi, Yoshida, Atsushi, Hayashi, Naoki, Hornberger, John, Yu, Tiffany, Chao, Calvin, Yoshizawa, Carl, Nakamura, Seigo
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4165904/
https://ncbi.nlm.nih.gov/pubmed/25190451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6963-14-372
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars